{"entity":{"id":"biolinerx","kind":"company","name":"BioLineRx","aka":["BioLineRx, Ltd.","BioLineRx Ltd."],"tldr":"BioLineRx is an Israeli company whose CXCR4 inhibitor motixafortide (Aphexda) was approved in the United States in 2023 to mobilise stem cells for autologous transplant in multiple myeloma, and which tests the drug with pembrolizumab in pancreatic cancer.","summary":"BioLineRx, based in Modi'in and listed on Nasdaq and Tel Aviv, develops motixafortide (BL-8040), a long-acting CXCR4 antagonist. In the phase 3 GENESIS trial a single dose with filgrastim mobilised enough stem cells for transplant in far more myeloma patients than filgrastim alone, leading to FDA approval as Aphexda in September 2023; US commercial rights were licensed to Ayrmid in 2024. The company also studies motixafortide with pembrolizumab and chemotherapy in metastatic pancreatic cancer and for sickle cell gene therapy mobilisation. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.biolinerx.com"},{"label":"ClinicalTrials.gov: trials led by BioLineRx","url":"https://clinicaltrials.gov/search?lead=BioLineRx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/BioLineRx"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["multiple-myeloma","pancreatic"],"sections":["supportive-care","targeted-therapy"],"technologies":[],"targets":["cxcr4"],"drugs":["pembrolizumab","filgrastim"],"companies":[],"institutions":[],"pathways":[],"terms":["autologous-transplant"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Modi'in","country":"IL","companyType":"biotech","website":"https://www.biolinerx.com","stage":"public","investors":[],"funding":[]},"route":"/companies/biolinerx/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"target":[{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/"}],"drug":[{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"autologous-transplant","kind":"term","name":"Autologous stem cell transplant (ASCT)","route":"/terms/autologous-transplant/"}]}}